Mr. Pratap Sandhu reports

THE PRECISION PEPTIDE COMPANY APPLAUDS FDA ACTION ADVANCING REGULATORY CLARITY FOR PEPTIDE THERAPIES

The Precision Peptide Company Inc. has commended the U.S. Food and Drug Administration for its recent actions to advance regulatory clarity surrounding peptide substances.

The FDA's decision to remove several peptides from Category 2 of bulk drug substances and refer them to further evaluation by the pharmacy compounding advisory committee marks a meaningful step toward establishing a more transparent and science-driven regulatory framework.

"Today, we took long-overdue action to restore science, accountability and the rule of law," stated U.S. health and human services secretary Robert F. Kennedy Jr. in a public statement.

The FDA confirmed that multiple peptides will undergo independent expert review based on "full clinical, pharmacological and safety evidence," signalling a shift toward evidence-based evaluation rather than broad classification.

"This is exactly the type of regulatory evolution the industry needs, and we are strong proponents of ensuring a responsible pathway to wellness and safe access to peptides for customers and patients," said Pratap Sandhu, chief executive officer of The Precision Peptide Company. "We believe that clear rules grounded in science will separate credible innovation from unregulated markets and ultimately benefit patients, providers and investors. We will continue to monitor developments arising from these regulatory changes and provide updates as appropriate."

Grant of stock options

In addition, the company is pleased to announce that it has granted an aggregate of 800,000 stock options to certain consultants in accordance with the omnibus long-term incentive plan of the company. The stock options are exercisable at a price of 50 cents per common share for periods ranging from one year to three years from the date of grant.

The common shares issuable upon exercise of the stock options are subject to a four-month hold period from the original date of grant.

We seek Safe Harbor.